Repligen (NASDAQ:RGEN) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

RGEN has been the topic of a number of other research reports. Wells Fargo & Company began coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Finally, JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Price Performance

Shares of RGEN opened at $142.58 on Friday. The company has a current ratio of 10.44, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The stock has a market cap of $7.99 billion, a P/E ratio of -385.34, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. The stock’s 50-day moving average price is $140.26 and its two-hundred day moving average price is $143.27.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share. On average, equities analysts predict that Repligen will post 1.52 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RGEN. Champlain Investment Partners LLC grew its stake in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after acquiring an additional 425,061 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC boosted its stake in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after acquiring an additional 199,322 shares during the period. Finally, DF Dent & Co. Inc. boosted its stake in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.